Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Translational studies leading to a clinical trial of PET imaging to evaluate the delivery of 89Zr-labeled pembrolizumab to brain metastases in patients with lung cancer enhanced by MRI-guided focused ultrasound
EF 2023-24
Résumé
Lung cancer is the most prevalent form of cancer worldwide and is the leading cause of cancer related deaths. Brain metastasis occurs in 40% of patients with lung cancer and is fatal. Brain metastases are difficult to treat because most drugs cannot cross the blood-brain-barrier and penetrate into the brain. A major advance in the treatment of lung cancer has been checkpoint immunotherapies such as pembrolizumab, which stimulate the immune system to attack cancer cells. However, the delivery of pembrolizumab across the blood-brain-barrier for the treatment of brain metastases is limited. MRI-guided focused ultrasound (MRIg-FUS) is a technique that applies ultrasound waves to the region of the brain where the tumour is located to disrupt the blood-brain-barrier and allow therapies to reach the tumour. Our collaborators at Sunnybrook Health Sciences Centre have launched the first clinical trial using MRIg-FUS to improve the uptake of pembrolizumab into brain metastases in patients with lung cancer. In my PhD research, I will develop a radiopharmaceutical that links pembrolizumab to the radioisotope zirconium-89 (89Zr) which can be imaged by positron emission tomography (PET). PET will be used in the trial to image the uptake of 89Zr-labeled pembrolizumab into tumours in the brain before and after MRIg-FUS. The goal is that this new approach will improve the uptake of pembrolizumab into brain metastases and hopefully increase the survival of lung cancer patients with brain metastases.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
496585
Name
Borlase Stephanie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Translational studies leading to a clinical trial of PET imaging to evaluate the delivery of 89Zr-labeled pembrolizumab to brain metastases in patients with lung cancer enhanced by MRI-guided focused ultrasound
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Blood-Brain-Barrier (Bbb); Brain Metastases; Lung Cancer; Mri-Guided Focused Ultrasound (Mrig-Fus); Pembrolizumab; Positron Emission Tomography (Pet); Radiopharmaceuticals; Zirconium-89 (89zr)
Abstract
Lung cancer is the most prevalent form of cancer worldwide and is the leading cause of cancer related deaths. Brain metastasis occurs in 40% of patients with lung cancer and is fatal. Brain metastases are difficult to treat because most drugs cannot cross the blood-brain-barrier and penetrate into the brain. A major advance in the treatment of lung cancer has been checkpoint immunotherapies such as pembrolizumab, which stimulate the immune system to attack cancer cells. However, the delivery of pembrolizumab across the blood-brain-barrier for the treatment of brain metastases is limited. MRI-guided focused ultrasound (MRIg-FUS) is a technique that applies ultrasound waves to the region of the brain where the tumour is located to disrupt the blood-brain-barrier and allow therapies to reach the tumour. Our collaborators at Sunnybrook Health Sciences Centre have launched the first clinical trial using MRIg-FUS to improve the uptake of pembrolizumab into brain metastases in patients with lung cancer. In my PhD research, I will develop a radiopharmaceutical that links pembrolizumab to the radioisotope zirconium-89 (89Zr) which can be imaged by positron emission tomography (PET). PET will be used in the trial to image the uptake of 89Zr-labeled pembrolizumab into tumours in the brain before and after MRIg-FUS. The goal is that this new approach will improve the uptake of pembrolizumab into brain metastases and hopefully increase the survival of lung cancer patients with brain metastases.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Borlase, Stephanie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~